Source: Biotechnology Innovation Organization
Publication Date: June 21, 2017
Former CNBC correspondent Mike Huckman interviews PaxVax President and CEO, Nima Farzan, at this year’s BIO 2017 conference.
Nima discusses vaccine development for underserved diseases, as well as differentiating PaxVax’s role as a leading independent vaccine company devoted to developing and commercializing specialty vaccines that protect against existing and emerging infectious diseases.
Nima highlights the work that PaxVax is doing to bring forth a Zika vaccine using Virus Like Particle (VLP) technology, as the virus has recently spread rapidly through the Caribbean, Latin America and more recently the US.
Nima discusses the need for new approaches to vaccine development, such as platforms that are scalable across multiple diseases, and describes the approach of the Coalition for Epidemic Preparedness Innovations (CEPI), whose mission is to prevent new epidemics, where funding is made available to multiple early stage opportunities in preparation of the emergence of an epidemic.
The interview concludes with a discussion on the beneficial impact vaccines continue to have on public health, and the need for the ability to breakthrough and control outbreaks such as cholera, which, at the time of the interview, had infected 100,000 people in Yemen in just three weeks.